## **Piramal Enterprises Limited**



Annual Report 2015-16

# Transforming consistently. Delivering value.

74%

CAGR of Annual Revenues over the last 28 years

CAGR of PBITDA over the last 28 years

Annualised return to shareholders over the last 28 years

₹24,900

Current market capitalisation of the Company<sup>2</sup>

Capital returned to shareholders through dividends and buyback till date

Over

Total value created <sup>3</sup>

- Assumed dividend re-invested in the stock
- Assumed a initial rate in the stock

  Market capitalisation as on May 31, 2016

  Merely less than ₹500 Crores of external capital raised till date. Includes initial capital invested in the company in 1988

#### Forward-looking statement

In this Annual Report, we have disclosed forward-looking information to enable investors to comprehend our prospects and take investment decisions. This report and other statements - written and oral - that we periodically make, contain forward-looking statements that set out anticipated results based on the management's plans and assumptions. We have tried, wherever possible, to identify such statements by using words such as 'anticipate', 'estimate', 'expects', 'projects', 'intends', 'plans', 'believes', and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward-looking statements will be realised, although we believe we have been prudent in our assumptions. The achievements of results are subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialise, or should underlying assumptions prove inaccurate, actual

'Change' is the only thing constant in the world. Companies which are able to embrace continuous 'change' to grow faster have come out as better performers than the rest. 'Change' involves implementing finite initiatives or executing a defined shift in the way an organisation carries out its activities, however, it may or may not encompass the whole organisation.

Unlike 'change', 'transformation' doesn't focus on a few discrete, defined shifts. It involves implementing a portfolio of initiatives. More importantly, the overall goal of 'transformation' is not just to execute a defined change, but to re-invent the organisation by discovering a new or revised business model, based on a vision for the future.

What distinguishes high performers from the rest is their ability to pull off this difficult feat of transformation - to move from the maturity stage of one business, to the growth stage of another business. Companies that remain most successful for a much longer period are the ones that make re-invention a regular part of their business strategy.

We, at Piramal Enterprises Limited (PEL) have followed this philosophy by demonstrating our ability to consistently transform, evolve and create positive changes. This applies throughout our history. We have displayed foresight and entrepreneurial acumen by identifying opportunities ahead of time and pursuing them diligently. The breadth and depth of our evolution over the years is a story of strategic soundness and efficient execution. Today, each of our businesses is a story of evolution and value-delivery.

PEL is now charting the path to its next leg of growth. With its three distinct and attractive business lines (Healthcare, Financial Services and Information Management), the Company is all set to emerge as market leaders in these areas.

This Annual Report captures our journey of consistent transformation and value creation. It also gives readers a glimpse of what to expect from us, next.

## Contents

STRATEGIC OVERVIEW	2-35
Piramal Enterprises at a Glance	2
Healthcare	4
Financial Services	6
Information Management	8
Chairman's Message	10
FY2016 Highlights	14
Our Journey of Transformation	15
Journey of Evolution - FY1989 to FY2010	16
Corporate Structure in FY2011	18
Journey of Evolution – FY2011 to FY2016	20
Corporate Structure in FY2016	22
Efficient Capital Allocation	24
Grown Consistently Every Quarter	25
Unparalleled Track Record	26
Near-Term Goal	27
Governance and Review Mechanism	28
Delivering Value to Stakeholders	32
MANAGEMENT DISCUSSION AND ANALYSIS	36-93
Financial Review	37
Operational Review-Healthcare	40
Operational Review-Financial Services	59
Operational Review-Information Management	69
Risk Management	75
Human Resources	78
Information Technology	82
Environment, Health and Safety	85
Corporate Social Responsibility	87
10-Year Financial Highlights	93
DOADD & MANAGEMENT DDOEH ES	04 101
BOARD & MANAGEMENT PROFILES Roard of Directors	<b>94-101</b>
Board of Directors	94
Board of Directors Management Team	94
Board of Directors	94
Board of Directors Management Team Awards and Recognition	94 99 102
Board of Directors Management Team Awards and Recognition STATUTORY REPORTS	94 99 102 <b>103-154</b>
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance	94 99 102 103-154 104
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report	99 102 103-154 104 118
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance	94 99 102 103-154 104
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report	94 99 102 103-154 104 118 126
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report	99 102 103-154 104 118
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE	94 99 102 103-154 104 118 126
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report	94 99 102 103-154 104 118 126
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report	94 99 102 103-154 104 118 126 155-275
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet	94 99 102 103-154 104 118 126 155-275
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss	94 99 102 103-154 104 118 126 155-275 154 162 163
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement	94 99 102 103-154 104 118 126 155-275 154 162 163 164
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement Notes to Financial Statements	94 99 102 103-154 104 118 126 155-275 154 162 163 164 166
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement Notes to Financial Statements	94 99 102 103-154 104 118 126 155-275 154 162 163 164 166
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report  Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement Notes to Financial Statements Form AOC-1	94 99 102 103-154 104 118 126 155-275 154 162 163 164 166
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement Notes to Financial Statements Form AOC-1  CONSOLIDATED Independent Auditors' Report Consolidated Balance Sheet	94 99 102 103-154 104 118 126 155-275 154 162 163 164 166 212
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement Notes to Financial Statements Form AOC-1  CONSOLIDATED Independent Auditors' Report Consolidated Balance Sheet Consolidated Statement of Profit and Loss	94 99 102 103-154 104 118 126 155-275 154 162 163 164 166 212 217 222 223
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement Notes to Financial Statements Form AOC-1  CONSOLIDATED Independent Auditors' Report Consolidated Balance Sheet Consolidated Statement of Profit and Loss Consolidated Cash Flow Statement	94 99 102 103-154 104 118 126 155-275 154 162 163 164 166 212 217 222 223 224
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement Notes to Financial Statements Form AOC-1  CONSOLIDATED Independent Auditors' Report Consolidated Balance Sheet Consolidated Statement of Profit and Loss	94 99 102 103-154 104 118 126 155-275 154 162 163 164 166 212 217 222 223
Board of Directors Management Team  Awards and Recognition  STATUTORY REPORTS Report on Corporate Governance Board's Report Annexures to Board's Report  FINANCIAL STATEMENTS STANDALONE Independent Auditors' Report Balance Sheet Statement of Profit and Loss Cash Flow Statement Notes to Financial Statements Form AOC-1  CONSOLIDATED Independent Auditors' Report Consolidated Balance Sheet Consolidated Statement of Profit and Loss Consolidated Cash Flow Statement	94 99 102 103-154 104 118 126 155-275 154 162 163 164 166 212 217 222 223 224

## PIRAMAL ENTERPRISES AT A GLANCE

Piramal Enterprises Limited (PEL) is a leading Indian business conglomerate, with its presence in Healthcare, Financial Services and Information Management sectors, across 100 countries and manufacturing bases in India, US, Europe and Canada.

#### **Our Purpose**

#### Doing Well and Doing Good

The values that guide our unique culture are embodied in our purpose: Doing Well and Doing Good. We believe that individual success and organisational growth cannot be exclusive of responsible and ethical business practices. Our purpose provides clear guidance to our people and ensures that we identify the right partners to create mutual, enduring value.

We stay true to our purpose of Doing Well and Doing Good by following three simple tenets:

#### o Making a positive difference

We aim to make a positive difference through our products, services, customer focus and innovation led research.

#### Serving people

We aim to serve people; our customers, community, employees, partners and stakeholders by putting their needs and well-being first.

#### Living our values

We live our values in our everyday actions, decisions and conduct at a personal as well as a corporate level.

The philosophy of Doing Well and Doing Good, along with our core values of Knowledge, Action & Care have been constant in our journey and serve as guideposts to help us become the company we would like to be.

#### **Our Values**

At Piramal Group, our core values of Knowledge, Action and Care have been an integral part of our guiding philosophy. These values represent our deeply held beliefs and define us at the individual as well as organisational levels.

Shaped by our past and collective experience, they determine how we engage with others, what we identify with and what we love and value.

We encourage a deep understanding of these core values and believe in institutionalising them across our entire organisation so as to build a distinctive Piramal culture.

#### Knowledge

#### **Expertise/Innovation**

- We strive for a deeper understanding of our domain.
- We aspire to do things creatively.

#### Action

#### **Entrepreneurship/Integrity**

- We are empowered to act decisively and create value.
- We are consistent in our thought, speech and action.

#### Care

#### Trusteeship/Humility

- We protect and enhance the interests of our customers, community, employees, partners and shareholders.
- We aspire to be the best, yet strive to be humble.

Among top 10

integrated global CDMOs offering both APIs and Formulations

Among the top

providers of financing to real estate developers in India


Among top 3

players in Inhalation Anaesthesia globally

#### **OUR BUSINESSES**








#### Movement in revenue mix (%)

Changing revenue mix over last few years




\* Others include treasury income.



#### Movement in capital employed mix\* (%)

Significant shift in the capital employed to the sectors generating high growth and strong returns



<sup>\*</sup>Excludes unallocated portion of capital employed

## Among the best

across globe in terms of quality, reliability and regulatory compliance in CMO space

## Among top 7

OTC players in India

### Gold standard

service provider of healthcare data, analytics, and insights





## Pharma Solutions (PPS)

FY2016 Revenues

₹2,290 Crores

18%

5- year Revenue CAGR

- Among the top integrated global Contract Development and Manufacturing Organisations (CDMOs) offering both APIs and Formulations
- 10 manufacturing facilities across the eastern and western parts of the world
- · All key sites are periodically approved by USFDA
- Address customers' needs across the drug life cycle
- Serve most of the top 7 global pharma companies
- World's leader in Antibody Drug Conjugates (ADCs)
- Growing faster-than-market over years

# Critical Care (PCC)

FY2016 Revenues

₹876 Crores

18%

5- year Revenue CAGR

- Among top three players in Inhalation Anaesthesia segment
  globally
- Only global company with all four generations of inhalation anaesthetic products
- Rapidly grew its global market share from 3% in FY2009 to 12% currently
- Presence in 118 countries, including a strong presence across major markets such as US, Europe and Japan
- State-of-the-art manufacturing facilities located in the US and India, in adherence to global standards

## Consumer Products (OTC)

FY2016 Revenues

₹393 Crores

18%

7- year Revenue CAGR

- Strong brand portfolio include key brands such as Saridon, i-pill and Lacto Calamine
- Most brands are among the top two in their respective markets
- In India's OTC market, the business has moved up from the 40th position in 2007 to 7th position currently
- Reaching to 3,50,000 outlets across 1,500 towns with 20,000+ population
- JV with Allergan is the India leader in ophthalmology





The Company has created its unique positioning in the financial services space through its strong presence in the following sub-segments:

# Wholesale Lending

Loan Book

₹13,048 Crores

25%+ RoE

- Lending to real estate developers and under special situation opportunities (in various sectors including renewables, cement, transportation, infrastructure, etc.)
- Largely invested in Mumbai, Pune, Bengaluru, Chennai, NCR and Hyderabad
- Entered 145 transactions with 81 leading developers
- Entered into Construction Finance during FY2015
- Managed by highly talented and experienced teams of 140 professionals, with a healthy mix of investing and operating experience
- Strategic alliances with large reputed partners like APG and CPPIR
- ~60% of the team is engaged in monitoring of assets

# Alternative Asset Management

**AUM** 

₹8,717 Crores

- Currently manages 7 funds, 3 third party mandates and 2 managed accounts
- Invested in 57 projects across 7 cities with 25 leading developers

# Investment in Shriram Group

Amount invested

₹4,583 Crores

Through investments in Shriram Group companies, the Company has an exposure to the retail financing segments such as used and new commercial vehicles, small and medium enterprises, consumer and gold loans, and other products such as life Insurance and general insurance.

- 20% stake in Shriram Capital (SCL). Invested ₹2,146 Crores.
- ~10% stake in Shriram Transport Finance (STFC).
   Invested ₹1,636 Crores.
- ~10% stake in Shriram City Union Finance (SCUF).
   Invested ₹801 Crores.
- Mr. Ajay Piramal is the Chairman of Shriram Capital.



